Write in a clean editor, then format for Biomarkers in Neuropsychiatry in one click — DocuGuru applies the official Elsevier template with numbered references and exports a submission-ready PDF plus the editable LaTeX source. Free to start.
Biomarkers in Neuropsychiatry is a peer-reviewed journal published by Elsevier, covering Tryptophan and brain disorders, Schizophrenia research and treatment, Functional Brain Connectivity Studies.
| Publisher | Elsevier |
|---|---|
| Reference style | Numbered (Elsevier) Numbered — [1], [2] in the text [1] A. Smith, B. Jones, C. Lee, A representative article title, Biomarkers in Neuropsychiatry 12 (2023) 45–58.
Formats any DOI in Biomarkers in Neuropsychiatry style. No sign-up. |
| Publishes research in | Tryptophan and brain disorders Schizophrenia research and treatment Functional Brain Connectivity Studies Stress Responses and Cortisol Alzheimer's disease research and treatments |
| ISSN | 2666-1446 |
| Citation impact (2-yr) | 2.87 |
| h-index | 20 |
| i10-index | 44 |
| Total citations | 1,478 |
| Article processing charge | $1,750 |
| Open access | Yes |
| Top institutions publishing here | Beth Israel Deaconess Medical Center |
| Journal website | www.journals.elsevier.com |
| You get | A submission-ready PDF and the editable LaTeX source — ready to submit. |
Citations each year’s papers have accumulated so far — the most recent years are still building up.
In 2018, there was a recent shift towards a biological definition of Alzheimer's disease (AD), based on biomarkers measured in vivo even before the onset of clinical dementia symptoms. No single biomarker can by itself accurately diagnose AD. A combination of biomarkers assessed through imaging and cerebrospinal fluid (CSF) yields better diagnostic accuracy. Although amyloid…
Investigators have increasingly turned to studying the retina as a window into brain structure and function. In neuropsychiatric diseases, retinal anatomy as assessed by optical coherence tomography (OCT) and retinal cell function as assessed by various forms of electroretinography (ERG) demonstrate notable changes. In addition, many studies indicate significant correlations between retinal changes and clinical…
The longstanding investigation of immune system abnormalities, including inflammation, in schizophrenia has tremendous renewed interest as an area of research. Presently, the field has an unparalleled opportunity to investigate inflammation as a potential biomarker in schizophrenia. In this review, we: 1) summarize evidence for inflammatory biomarkers across the course of illness, 2) discuss relationships between…
Motor abnormalities (e.g., dyskinesia, psychomotor slowing, neurological soft signs) are core features of schizophrenia that occur independent of drug treatment and are associated with the genetic vulnerability and pathophysiology for the illness. Among this list, psychomotor slowing in particular is one of the most consistently observed and robust findings in the field. Critically, psychomotor slowing…
Biomarkers in Parkinson’s disease are widely researched in the field of neuropsychiatry. Though Parkinson’s disease is diagnosed clinically, biomarkers prove to be a promising means to identify disease in early stages, track disease progression, and distinguish Parkinson’s disease from other conditions like dementia with Lewy bodies. There is debate on the level of clinical utility…
